Press Release

Date: October 29, 2026 To, To, Sr. General Manager Sr. General Manager Listing Department Listing Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, C-1, Block G Dalal Street Bandra Kurla Complex Mumbai – 400 001 Bandra (E), Mumbai – 400 051 BSE Scrip Code: 544319 NSE Symbol: SENORES Sub.: Submission of Media Release Dear Sir/Ma’am, Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith a Media Release in relation to the Un-audited Consolidated and Standalone Financial Results of the Company for the quarter and half year ended September 30, 2026 duly approved by the Board of Directors of the Company at their meeting held on October 29, 2026. You are requested to take the same on your record. Thanking you. For Senores Pharmaceuticals Limited Shilpa Sharma Company Secretary & Compliance Officer Membership Number: A34516 Enclosure: As above Senores Pharmaceuticals Limited 1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park, Ambali Bopal Road, Ahmedabad‐380054, Gujarat, India P: +91 79 2999 9857 | E: info@senorespharma.com W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263 Media Release SENORES PHARMACEUTICALS LIMITED Robust Financial & Operational Performance in Q2 and H1 FY27 Highest-ever quarterly Revenue and EBITDA in Q2FY27 Ahmedabad, Gujarat, 29th October 2026 – Senores Pharmaceuticals Limited, a global research driven pharmaceutical company engaged in developing and manufacturing specialty, niche and complex products for Regulated and Emerging Markets, announced its unaudited Financial Result for the quarter and half year ended 30th September 2026. Q2 FY27 CONSOLIDATED FINANCIAL HIGHLIGHTS Revenue EBITDA PAT ₹ 192 crs ₹ 58 crs ₹ 37 crs +25% +38% +22% Y-o-Y Y-o-Y Y-o-Y H1 FY27 CONSOLIDATED FINANCIAL HIGHLIGHTS Revenue EBITDA PAT ₹ 373 crs ₹ 111 crs ₹ 67 crs +30% +58% +31% Y-o-Y Y-o-Y Y-o-Y Q2 & H1 FY27 SEGMENTAL HIGHLIGHTS Segment Revenue (₹crs) Q2FY27 Q2FY26 Y-o-Y H1FY27 H1FY26 Y-o-Y Regulated Markets 136.7 106.9 27.9% 264.5 196.9 34.3% Emerging Markets 38.4 31.7 21.2% 76.0 60.7 25.3% Branded Generics 9.5 11.9 -20.5% 17.5 20.2 -13.4% Others 7.8 3.4 126.2% 14.6 8.7 67.2% Total Revenue 192.3 153.9 24.9% 372.5 286.5 30.0% Media Release Q2 and H1 FY27 PERFORMANCE HIGHLIGHTS  Consistently strong and broad-based growth across businesses • Consistently delivering robust performance. Revenue for Q2 and H1 FY27 growing by 25% and 30% Y-o-Y respectively. • Regulated & Emerging Market revenues grew by 34% & 25% respectively on a Y-o-Y basis in H1.  Robust improvement in profitability • EBIDTA for Q2 and H1 FY27 grew by 38% and 58% with margin expansion of ~290 bps and ~530 bps on a Y-o-Y basis respectively. • EBITDA could have been even higher but for initial set-up and operating costs associated with Zoraya and Amerisyn, without corresponding revenue generation.  Continued expansion of product portfolio • Nearly doubled our Regulated Markets portfolio, expanding from 34 ANDAs as of September 2025 to 64 ANDAs as of September 2026, out of which 23 ANDAs have been commercialized.  Improvement in cash flow generation • Cash from Operations stood at ₹ 38 crores in H1FY27, consistent improvement in cash flow generation trajectory over the last 12-18 months.  Emerging Markets on Steady Trajectory • Emerging Markets business on a steady growth trajectory. Revenue growing by 21% and 25% Y-o-Y in Q2 and H1 FY27 respectively. Increasing focus on niche products and streamlined go-to-market strategies.  Outlook remains positive • On track to deliver 30-40% revenue growth and 50-60% PAT growth in FY27. This is underpinned by a robust product pipeline, with strong visibility of commercial launches over the course of the year. Media Release Commenting on the performance, Mr. Swapnil Shah, Managing Director, Senores Pharmaceuticals Limited said, “We delivered another robust performance in Q2 and H1 FY27, marking our 9th consecutive quarter of healthy double-digit growth. Strong execution, operational excellence and diversified business operations continue to drive growth and strengthen our business fundamentals. Our Regulated Markets business sustained strong momentum, with our ANDA portfolio nearly doubling to 64, including 23 commercialized products and 41 planned launches over the next 18–24 months. Strong launch readiness, the scaling up of our Apnar facility, and the upcoming contributions from Zoraya and Amerisyn provide clear growth visibility. Our CDMO/CMO opportunities and pipeline of 41 molecules covering approximately 130 strengths further strengthen our growth platform. Our Emerging Markets business continued to grow, with improving profitability and positive cash flows. Entry into Europe and the anticipated PIC/S approval for our Chhatral facility are expected to expand market access and support future growth. In India, investments in field-force expansion and market reach position our critical care injectables business for steady progress. Operating cash flow improved to ₹38 crore in H1 FY27, compared with ₹31 crore in the previous year. While initial costs for Zoraya and Amerisyn temporarily impacted profitability, their anticipated scale-up from FY28 onwards is expected to drive operating leverage and improve margins. Backed by a robust product pipeline, expanded manufacturing capabilities and strong commercial launch visibility, we remain on track to deliver 30–40% revenue growth and 50–60% PAT growth in FY27, followed by anticipated annual growth of 20–25% over the next two years.” Media Release About Senores Pharmaceuticals Limited: Senores Pharmaceuticals Limited is a globalresearch-driven pharmaceuticalcompanyengaged indeveloping and manufacturing a widerangeofpharmaceuticalproductspredominantlyfortheUS,Canada,andotherregulatedandemergingmarketsacrossvarious therapeuticareasanddosageforms. Thecompanies’currentportfolioincludes64ANDAsand19CMO/CDMOcommercialproductsthatarepermittedfordistributionin the USA. Senores is also engaged in the development and manufacturing of complex generics certified by global food and drugs authoritiesanddeliversgenericdrugsforemergingmarketscateringtomorethan40countries.Thecompanyhascurrentlyapproval fromregulatorybodiesofmorethan10countriesforitsmanufacturingfacilityinChhatralforemergingmarketswith558product registrationsand944productapplications.SenoresalsomanufacturescriticalcareinjectablesandActivePharmaceuticalIngredients (API). Senores has 3 manufacturing facilities for formulations – one in Atlanta, US which is USFDA approved and DEA/BAA compliant, secondinGujarat,which isalsoUS-FDAapprovedandthethirdinChhatral,Ahmedabad,IndiaapprovedbyWHO-GMPtocaterto Emerging Markets.Thecompanyalsohas2manufacturingfacilitiesforAPI inIndia,both locatedaroundAhmedabad,withonein ChhatralandtheotherinNaroda.SenoreshasstrongR&Dcapabilitiestodrivedifferentiatedproductportfolioacross3R&Dsites(1 intheUSAand2inIndia). Safe Harbour Statement: Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plansandobjectives,theprogressandresultsofresearchanddevelopment,potentialprojectcharacteristics,projectpotentialand target dates for projectrelated issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptionsorotherfactors. For more information, please contact Company : SENORES PHARMACEUTICALS LIMITED CIN: L24290GJ2017PLC100263 Mr. Deval Shah – Whole Time Director & CFO Email: [Showing first 8,000 characters — download PDF for full document]